Market News & Trends
Medigene Announces Pipeline Expansion Into Neoantigens With Programs Targeting Multiple KRAS Mutations & HLAs
Medigene AG recently announced its pipeline expansion into neoantigens (also known as oncogenic driver mutations) with KRAS (Kirsten rat sarcoma viral oncogene homologue) as the…
Wheeler Bio and Charles River Laboratories Announce Agreement to Build & Operate RightSource Laboratory
Wheeler Bio, Inc. and Charles River Laboratories International, Inc. recently announced an agreement to implement RightSource at Wheeler Bio’s current good manufacturing practice (cGMP) biologics manufacturing facility….
Upperton Pharma Solutions Increases Oral Dosage Form Capabilities at Its Nottingham HQ
Upperton Pharma Solutions has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced…
Coave Therapeutics Announces Positive 12-Month Data From Ongoing Phase 1/2 Clinical Trial of CTx-PDE6b in Patients With Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
Coave Therapeutics recently announces the positive 12-month results from its Phase 1/2 trial evaluating the safety and efficacy of its innovative gene therapy, CTx-PDE6b, for…
Minoryx Gains FDA Approval to Initiate Phase 3 Trial in Patients With Cerebral Adrenoleukodystrophy
Minoryx Therapeutics recently announced US FDA approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD)…
Evonik Launches Next-Generation Peptide for Biopharma Applications
Evonik now offers cQrex® KC, a performance-boosting peptide for cell culture media used in the manufacture of biological drugs. The new peptide enables cell culture process developers….
Positive Phase 2 Data of Novel Investigational Anti-CD40L Antibody Frexalimab Show Significantly Reduced Disease Activity in Relapsing Multiple Sclerosis
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation…
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
MetrioPharm AG recently announced the US FDA has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy. DMD is the most…
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
Silo Pharma, Inc. recently announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated…
OLON Enters ADC Market
OLON Group recently announced the start of construction of a new facility at its Rodano site (Milan, Italy) which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for antibody-drug conjugates (ADCs), one of the….
LIXTE Biotechnology’s Lead Clinical Compound Increases Effectiveness of Cancer Immunotherapy
LIXTE Biotechnology Holdings, Inc. recently announced a recently published article in the journal Cancer Research showed that PP2A, the pharmacologic target of LIXTE’s lead clinical…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development
Catalent recently announced it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage, kitting, and distribution of advanced…
Transgene & BioInvent Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors
Transgene and BioInvent International AB recently announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent BT-001 in 18 patients has now been….
Oxford BioTherapeutics & Boehringer Ingelheim Agree on 2-Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
Oxford BioTherapeutics Ltd. recently announced it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional 2 years. With this extension, further programs will….
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
Apellis Pharmaceuticals, Inc. recently announced the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its…
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of Highly Differentiated Antibiotic for Severe Hospital Infections
Antabio SAS recently announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next- generation antibacterial combination that has been…
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
BriaCell Therapeutics Corp. recently announce it has entered into an arrangement agreement dated May 24, 2023, with BriaPro Therapeutics Corp. (SpinCo) pursuant to which certain…
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Revvity, Inc. recently announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a…
Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections
Viridian Therapeutics, Inc. recently announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse innovative wearable drug delivery system for….
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
ImmunOs Therapeutics AG recently announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia. IOS-1002 is a…
